Intelligent Bio Solutions Inc. INBS
Set alert
1.76 USD -0.07 -3.83%
At close · Oct 30
1.76 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.69 Day range 1.82
1.44 52-week range 17.92
- YTD
- -81.53%
- 1 year
- -82.91%
- Open
- 1.81
- Prev close
- 1.83
- Mkt cap
- 5.84M
- Vol
- 18.22K
- Avg vol
- 146.02K
- EPS
- -8.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.69
- High
- 1.82
- Forward P/E
- 3.83
- Beta
- 4.72
- Short ratio
- 1.25
- Inst. own
- 14.38%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2025
- 50-d avg
- 1.53
- 200-d avg
- 2.07
- 1y target
- 0.00
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 5.88M
- Enterprise value
- 769.49K
- Trailing P/E
- 0.00
- Forward P/E
- 3.83
- PEG ratio
- 0.00
- Price / sales
- 1.89
- Price / book
- 0.56
- EPS (TTM)
- -2.30
- Beta
- 4.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.11M
- Revenue growth
- 64.20%
- Free cash flow
- -5.87M
- Total cash
- 6.42M
- Total debt
- 871.44K
- Return on equity
- -171.71%
- Shares outstanding
- 4.39M
- Short % of float
- 8.73%
- 50-day average
- 1.53
- 200-day average
- 2.07
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Feb 14, 2025
Expected Feb 14, 2025. Consensus EPS estimate 0.00.
Financials — quick view
INBS Revenue — quarterly 1.39M
INBS Net income — quarterly -3.91M
INBS EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 14, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.70 | — | — |
| Sep 19, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -1.43 | — | — |
| Feb 9, 2024 | Dec 1, 2023 | -3.24 | — | — | — |
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse. It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York. The company operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- ibs.inc
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Intelligent Bio Solutions Registers 6,211,809 Shares Of Common Stock For Resale Underlying Warrants
- Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
- Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market
- Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on INBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| SAKIRIS SPIRO KEVIN | Chief Financial Officer | Stock Award(Grant) | Sep 24, 2024 | 53,759 |
| SIMEONIDIS HARRY | Chief Executive Officer | Stock Award(Grant) | Sep 24, 2024 | 40,408 |
| TOWERS CHRISTOPHER | Director | Purchase | Oct 3, 2023 | 9,880 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alyeska Investment Group, L.p. | 4.70% | 206,199 | 276.31K | Sep 29, 2024 |
| CVI Holdings, LLC | 1.82% | 79,843 | 106.99K | Jun 29, 2024 |
| Geode Capital Management, LLC | 0.52% | 22,706 | 30.43K | Sep 29, 2024 |
| Vanguard Group Inc | 0.35% | 15,485 | 20.75K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 0.12% | 5,389 | 7.22K | Sep 29, 2024 |
| UBS Group AG | 0.04% | 1,551 | 2.08K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.40% | 17,641 | 23.64K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.35% | 15,485 | 20.75K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 5,599 | 7.50K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 4,097 | 5.49K | Oct 30, 2024 |